IPSC Stock Summary and Trading Ideas (Century Therapeutics | NASDAQ:IPSC)

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Century Therapeutics trades on the NASDAQ stock market under the symbol IPSC.

As of September 9, 2026, IPSC stock price declined to $2.03 with 289,446 million shares trading.

IPSC has a beta of 1.72, meaning it tends to be more sensitive to market movements. IPSC has a correlation of 0.04 to the broad based SPY ETF.

IPSC has a market cap of $367.58 million. This is considered a Small Cap stock.

In the last 3 years, IPSC traded as high as $5.51 and as low as $.34.

The top ETF exchange traded funds that IPSC belongs to (by Net Assets): VTI, VXF, VTWO, OMFS, AVSC.

IPSC has outperformed the market in the last year with a return of +297.8%, while the SPY ETF gained +18.7%. However, in the most recent history, IPSC shares have underperformed the stock market with its stock returning -4.2% in the last 3 month period and -6.5% for the last 2 week period, while SPY has returned +3.4% and -0.5%, respectively.

IPSC support price is $2.00 and resistance is $2.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IPSC shares will trade within this expected range on the day.